FDA Clears First Epinephrine Autoinjector for Infants

The US Food and Drug Administration (FDA) has approved the first and only epinephrine autoinjector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and children weighing 16.5 to 33 pounds (7.5 to 15 kg), according to a company statement.

Auvi-Q is a compact epinephrine auto-injector with industry-first features, including a voice prompt system that guides a user with step-by-step instructions through the delivery process, and a needle that automatically retracts following administration. The new 0.1 mg-dose epinephrine auto-injector has a shorter needle length and lower dose of epinephrine than current FDA approved 0.15 mg and 0.3 mg epinephrine auto-injectors.

Leave a Reply

Your email address will not be published. Required fields are marked *